SGCB and type 1 diabetes mellitus: The present study demonstrates that sGC activation by cinaciguat restored the glomerular cGMP content, reduced TGF-ß1 expression and ERK1/2 phosphorylation attenuating podocyte injury, proteinuria, glomerular cell proliferation and apoptosis in the rat model of type-1 diabetes.